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The purpose of this paper is to introduce and describe the Prostate Imaging and Reporting Archiving Data System (PI-RADS). For
every single parameter the PI-RADS scoring system will be explained and magnetic resonance imaging (MRI) examples will be
given. In the end two patient cases are presented to explain the overall interpretation score in multiparametric imaging.
1. Introduction
At present, multiparametric magnetic resonance imaging
(MRI) is the most sensitive and specific imaging technique
for localizing prostate cancer (PCa) [1]. According to a group
of prostate MRI experts from the European Society of Uro-
genital Radiology (ESUR) multiparametric MRI should at
least consist of high-resolution T2-weighted imaging (T2WI)
in combination with two functional techniques, such as
dynamic contrast-enhanced (DCE) MRI, diffusion-weighted
imaging (DWI) or proton spectroscopy imaging (MRSI) [2].
The most important reason for this is that T2WI is the
main important parameter to picture the prostate anatomy,
and DCE-MRI adds sensitivity [3, 4] in PCa detection and
DWI [5–7] and MRSI [8, 9] improve the specificity of PCa
characterization.
Nevertheless, interpretation of multiparametric MR
images is still subjective. For other organs, for example, the
breast, liver, and thyroid gland, standardized interpretation
schemes including risk stratification criteria have been
developed to determine the presence of malignancy. The
most developed and eminent system is the Breast Imaging
Reporting and Data System (BI-RADS).
Inspired by BI-RADS and to improve the diagnostics
of PCa, the same group of prostate MR imaging experts
published in 2012 a set of clinical guidelines with the
aim to standardize the interpretation and to report the
different parametric MR-techniques: the Prostate Imaging
and Reporting Archiving Data System (PI-RADS) [2]. Major
goals of this system are to allow comparison of interobserver
interpretation variability; to reduce this variability by dis-
cussing the individual scores; to enhance communication
with clinicians in a uniform way; to facilitate quality assur-
ance and research; and to improve patient outcome.
The purpose of this paper is to introduce and describe the
PI-RADS system by means of MR imaging examples.
2. PI-RADS Scoring System
In the next sections the PI-RADS scoring criteria are
explained for all parameters except MRSI. MRSI is, in
contrast to T2WI, DWI, and DCE, considered as an optional
parameter by the ESUR guidelines and is therefore not
discussed in this report. Every parameter, T2WI, DWI, and
DCE, is scored independently on a 5-point scale, where score
1 means that clinically significant disease is highly unlikely;
score 2 means that clinically significant disease is unlikely to
be present; score 3 indicates that the presence of clinically
significant cancer is equivocal; score 4 means that clinically
significant cancer is likely to be present; score 5 indicates that
clinically significant cancer is highly likely to be present. Since
the different parameters are not always unanimous in their
scoring, the overall interpretation of each lesion is clarified in
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Figure 1: Examples of PI-RADS scoring for T2WI in the peripheral zone. (a) PI-RADS 1. (b) PI-RADS 2. (c) PI-RADS 3. (d) PI-RADS 4. (e)
PI-RADS 5.
the end and a final score is given to predict its chance of being
a significant cancer.
3. T2-Weighted Imaging
Overall, high-resolution T2-weighted imaging (T2WI) pro-
vides the best images to assess the anatomy of the prostate
and its adjacent structures as the bladder, seminal vesicles,
and rectal wall. In diagnosing prostate cancer it is a sensitive
technique; however, it is not very specific.
From a radiological point of view the prostate consists
out of two different zones: the peripheral zone, located
posteriorly and inferiorly, and the central gland, located
anteriorly and superiorly [10]. Anatomically, the central gland
can be divided into the transition zone and the central zone.
With increasing age, the composition of the central gland
changes. In young men it is mainly composed of the central
zone, but in older men it is mainly composed of transition
zone, due to the development of benign hyperplasia (BPH),
which leads to the formation of adenomatous nodules.
Given the distinct anatomical appearance of both zones
on T2WI, two different sets of PI-RADS criteria are devel-
oped: one for the peripheral zone and another for the tran-
sition zone.
3.1. Peripheral Zone. In Table 1 the PI-RADS criteria for the
peripheral zone are shown. A healthy normal peripheral zone
(PI-RADS 1) has a uniformhigh signal intensity as depicted in
Figure 1(a). Linear, wedge-shaped, geographic areas of lower
signal intensity with no clear delineation and no mass effect
Table 1: PI-RADS scoring system for T2WI—peripheral zone.
PI-RADS
score Criteria
1 Uniform high signal intensity
2 Linear, wedge-shaped, or geographic areas of lowersignal intensity, usually not well demarcated
3 Intermediate appearances not in categories 1/2 or 4/5
4 Discrete, homogeneous low signal focus/massconfined to the prostate
5
Discrete, homogeneous low signal intensity focus
with extracapsular extension/invasive behavior or
mass effect on the capsule (bulging), or broad
(>1.5 cm) contact with the surface
usually indicate nonmalignant conditions such as prostatitis,
atrophy, scar tissue, hematomas, postradiation changes, or
hormonal effects [11–13]. These lesions can be scored as PI-
RADS 2. Figure 1(b) shows a typical PI-RADS 2 lesion in the
left peripheral zone because it is wedge-shaped and shows no
mass effect.
Prostate cancer can appear as a focal area of low signal
intensity, with decreasing signal intensity when the Gleason
grade increases. A discrete, homogenous focus or mass with
low signal intensity and still confined to the prostate is scored
as PI-RADS 4 and is shown in the right peripheral zone in
Figure 1(d). When this focus shows extracapsular extension
or invasive behavior, mass effect on the capsule (bulging),
or more than 1.5 cm capsule contact, it is highly likely to be
clinically significant prostate cancer and should therefore be
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Figure 2: Examples of PI-RADS scoring for T2WI in the transition zone. (a) PI-RADS 1. (b) PI-RADS 2. (c) PI-RADS 3. (d) PI-RADS 4. (e)
PI-RADS 5.
scored as PI-RADS 5. In Figure 1(e) a lesion with mass effect
on the capsule and probable extracapsular extension is seen
in the right peripheral zone.
A PI-RADS 3 score should be given when the lesion does
not appear as described in the other categories. An example
is given in Figure 1(c): the area in the left anterior horn of
the peripheral zone is a PI-RADS 3 lesion because it is well
demarcated and therefore cannot be scored as a PI-RADS 2,
and as it does not show homogenous low signal intensity it
cannot be scored as PI-RADS 4 as well.
3.2. Transition Zone. The PI-RADS criteria for scoring a
lesion in the transition zone on T2WI are shown in Table 2.
On T2WI a normal transition zone can be described as areas
of low signal intensity alternated with round, well-defined
BPH nodules with an inhomogeneous signal intensity, in
a pattern described as “organized chaos” as depicted in
Figure 2(a). The presence of clinical significant cancer is
highly unlikely here; for this reason this can be scored as
PI-RADS 1. When one or more of these areas show well-
marginated homogenous signal intensity, for example, the
indicated nodule on the right side in Figure 2(b), this should
be scored as PI-RADS 2.
A focal, ill-defined area showing homogenous low signal
intensity, also described as “erased charcoal drawing sign,”
visible in Figure 2(d) in the ventral left part of the prostate,
should be scored as PI-RADS 4. When this area involves
the anterior fibromuscular stroma, extends into the anterior
horn of the peripheral zone, and is lenticular or water-drop-
shaped, it should be scored as PI-RADS 5. In Figure 2(e)
the large lesion with erased charcoal drawing sign and
Table 2: PI-RADS scoring system for T2WI—transition zone.
PI-RADS
score Criteria
1 Heterogeneous transition zone adenoma withwell-defined margins: “organized chaos”
2
Areas of more homogeneous low signal intensity,
however well-marginated, originating from the
transition zone/BPH
3 Intermediate appearances not in categories 1/2 or 4/5
4 Areas of homogeneous low signal intensity, illdefined: “erased charcoal drawing sign”
5
Same as 4, but involving the anterior fibromuscular
stroma sometimes extending into the anterior horn
of the peripheral zone, usually lenticular or
water-drop- shaped
involving the anterior fibromuscular stroma ventrally is a
typical example of a PI-RADS 5 lesion. If the lesion does
not fit in the criteria described above, it should be scored as
PI-RADS 3. An example is given in Figure 2(c). This lesion
in the left side of the prostate has a well-defined margin
and could be scored as PI-RADS 2; however some erased
charcoal effect is present, indicating PI-RADS 4. Because of
the aforementioned reasons, it is neither a clear PI-RADS 2
nor a PI-RADS 4 lesion, and therefore scored as PI-RADS 3.
4. DWI
Diffusion-weighted imaging shows the randommovement of
water molecules in tissue. In tissues with high cellular density
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and intact cell membranes, for example, cancer or fibrosis,
water molecules can hardly move. Then, the diffusion-
weighted images will show diffusion restriction represented
by a high signal intensity on the high 𝑏-value images and low
signal intensity on the apparent diffusion coefficient (ADC)
maps. ADC maps correlates well with tumor aggressiveness
and therefore improves specificity in examining prostate MR
images [5]. More technical details about diffusion-weighted
imaging can be read in the report of Qayyum [14].
Normal glandular prostate tissue (PI-RADS 1)will give no
signal reduction on the ADC map and no increase in signal
intensity on the high 𝑏-value images. An example is shown
in Figure 3(a). On the left side the ADC-map is shown with
particular in the peripheral zone high signal intensity and on
the right side the calculated 𝑏1400 image shows equal signal
intensity in the entire prostate.
A typical PI-RADS 2 lesion is represented by diffuse
hypersignal intensity on high 𝑏-value images. Low ADC val-
ues; no focal features, however, linear, triangular or geograph-
ical elements are allowed.This is depicted in Figure 3(b), both
the left and right peripheral zones show hypointense signal
on the ADC map and diffuse high signal intensity on the
calculated 𝑏1400 image.
When the ADC-map shows focal area(s) of reduced ADC
together with isointense signal intensity on high 𝑏-value
images, as depicted in the right transition zone in Figure 3(d),
PI-RADS score 4 should be reported. A focal mass or area
showing reduced ADC as well as hyperintense signal on the
high 𝑏-value images is characteristic for PI-RADS 5. A typical
example of a lesion with these characteristics is given in the
left transition zone of the prostate in Figure 3(e).
If the diffusion-weighted images show intermediate
appearances andno characteristics of categories 1/2 or 4/5, PI-
RADS score 3 should be reported. In Figure 3(c) a PI-RADS
3 lesion is shown. On the ADCmap no clear signal reduction
is seen, whereas on the calculated 𝑏1400 image a focal lesion
with high signal intensity is represented on the right dorsal
side of the prostate. Based on the ADCmap this lesion should
be scored as PI-RADS 1; however based on the high 𝑏-value
image the lesion should be scored as PI-RADS 5. Because it
is neither a clear PI-RADS 1 lesion nor a clear PI-RADS 5
lesion, it was scored as PI-RADS 3.Anoverviewof the scoring
criteria is shown in Table 3.
5. DCE
Dynamic contrast-enhanced (DCE)MRI is based on the per-
meability of blood vessels and extravasation of contrast agent
into the adjacent tissue. Leaky endothelia with an increased
permeability and therefore fast contrast enhancement are a
typical feature for PCa.
The PI-RADS scoring system for DCE imaging works
different from the other parameters. These criteria are cur-
rently under discussion because according to some studies
DCE-MRI does not seem to add significant value to the
diagnosis of PCa [15, 16]. Other studies state that DCE-MRI
can detect PCa with both high sensitivity and specificity
and helps in tumor staging [17, 18]. Because of this debate,
Table 3: PI-RADS scoring system for DWI.
PI-RADS
score Criteria
1
No reduction in ADC compared to normal glandular
tissue. No increase in signal intensity on any high
𝑏-value images∗
2
Diffuse hypersignal intensity on high 𝑏-value
images∗ with low ADC; no focal features, linear,
triangular, or geographical features, allowed
3 Intermediate appearances not in categories 1/2 or 4/5
4 Focal area(s) of reduced ADC but isointense signalintensity on high 𝑏-value images∗
5 Focal area/mass of hypersignal intensity on the high
𝑏-value images∗ with reduced ADC
∗(≥b800).
Table 4: PI-RADS scoring system for DCE.
PI-RADS
score Criteria
1 Type 1 enhancement curve
2 Type 2 enhancement curve
3 Type 3 enhancement curve
+1 For focal enhancing lesion with curve types 2-3
+1 For asymmetric lesion or lesion at an unusual placewith curve types 2-3
criteriawill bemodified almost certainly in the next PI-RADS
version. Nevertheless, the current criteria for DCE-scoring
are described in Table 4.
The first step is to determine which signal-intensity-over-
time curve type fits the enhancement pattern of the lesion.
Typical examples of the different curve types (1, 2, and 3)
are shown in Figure 4. If the curve type is known, the
accompanying PI-RADS score should be given.
Curve type 1 can be described as slowly increasing
enhancement over time, curve type 2 is characterized by
enhancement reaching a plateau phase, and curve type 3
shows fast enhancement with washout effect afterwards.
When a curve type 2 or 3 is present, the second step is to
verify whether the specific lesion is a focal enhancing lesion.
If yes, one point should be added to the PI-RADS score. The
third step is to determine whether the lesion is asymmetric or
is located at an unusual place. If yes, again add another point
to the PI-RADS score. In this way a maximum score of PI-
RADS 5 can be achieved.
In Figure 5(a) aDCE-imagewith the typical enhancement
pattern of BPH is shown. The enhancement has a curve type
3, is not focal and not asymmetric, and is therefore scored
as PI-RADS 3. In Figure 5(b) a prostate with an enhancing
lesion in the ventral part of the prostate is shown. Again, a
type 3 enhancement curve is shown. One point can be added
to the PI-RADS score because it is a focal enhancing lesion,
ending up with a final PI-RADS score of 4. Figure 5(c) shows
a focal, asymmetric enhancing lesion in the right peripheral
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Figure 3: Examples of PI-RADS scoring for DWI. Left: axial ADC map. Right: axial DWI with calculated 𝑏 = 1400. (a) PI-RADS 1. (b)
PI-RADS 2. (c) PI-RADS 3. (d) PI-RADS 4. (e) PI-RADS 5.
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Figure 4: Examples of PI-RADS scoring for DCE. (a) Curve type 1. (b) Curve type 2. (c) Curve type 3.
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Figure 5: Examples of PI-RADS scoring for DCE. (a) PI-RADS 3. (b) PI-RADS 4. (c) PI-RADS 5.
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Figure 6: Example of multiparametric MR images of an 83-year-old male, with a PSA level of 10 ng/mL and 0 negative transrectal ultrasound
guided biopsy sessions. The encircled lesion scored PI-RADS score 5 on T2W, DWI, and DCE images. Because the lesion is located in the
peripheral zone, DWI is the dominant parameter and the final PI-RADS score was PI-RADS 5. (a) Axial T2-weighted image. (b) Axial ADC
map. (c) Axial DWI with 𝑏 = 1400. (d) Axial DCE image. (e) Curve of the DCE image.
zone with curve type 3 and can therefore be scored as PI-
RADS 5.
6. Overall Interpretation
The ESUR guidelines provide explicit criteria for how to rate
a lesion for every specific MRI parameter, but a consistent
instruction on how to calculate the overall PI-RADS score
is lacking. Since these guidelines were published, several
research groups validated the PI-RADS score and most of
them calculated a PI-RADS sum score (scale from 3 to 15)
by summation of the 3 single scores [16, 19–24].
Another method to assign a final PI-RADS score is not
to use the sum score of all different parameters, but rather an
overall interpretation score, identical to the BI-RADS system.
Thismeans that the final score will not be in the range of 3–15,
but in the range of 1–5.
The ESUR prostate MRI expert group and the PI-RADS
steering committee of the American College of Radiology
(ACR) recently have reached consensus how to classify this
final PI-RADS score. In brief, it will contain the following:
in case all individual parameters indicate the same level of
suspicion for the presence of clinically significant Pca, for
instance, T2WI, DWI, and DCE are all scored as PI-RADS
5, the overall PI-RADS score should be 5 as well. When not
all parameters are consistent in determining the presence of
clinically significant cancer, the new classification method
prescribes that the “dominant” parameter should determine
the overall PI-RADS score. The dominant parameter for
cancer suspicious lesions in the peripheral zone is DWI, for
transition zone lesions it is T2WI, and for lesions suspicious
for PCa recurrence it is DCE. This method will be published
in the second half of 2014 as modification to the current
ESUR guidelines. Recently, part of this is also suggested by
Baur et al. After evaluation of the current PI-RADS system,
they concluded that assigning a DWI score for peripheral
zone lesions and a T2WI score for transition zone lesions was
sufficient for stratification of patients for further diagnostic
workup [16].
Themultiparametric images of Figure 6 show an example
where all parameters show the same PI-RADS score. These
images were acquired in an 83-year-old male with a PSA level
of 10 ng/mL and no previous biopsy sessions. On the T2-
weighted images a large lesion with low signal intensity and
broad capsule contact in the peripheral zone is present. This
is scored as PI-RADS 5. The same lesion shows hypointense
signal on the ADC map and hyperintense signal on the
calculated 𝑏1400 image (PI-RADS 5). DCE shows a curve
type 3 with enhancement in an unusual region (PI-RADS 5).
For these reasons, the final PI-RADS score is 5 as well. The
presence of clinical significant cancer was histopathologically
confirmed with MR-guided biopsy, showing a Gleason 5 + 4
= 9.
In Figure 7 the multiparametric MR images of a 68-year-
old male are shown. This man had a PSA level of 40 ng/mL
and had 3 negative transrectal ultrasound guided biopsy
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Figure 7: Example of multiparametric MR images of a 68-year-old male, with a PSA level of 40 ng/mL and 3 negative transrectal ultrasound
guided biopsy sessions. The encircled lesion scored PI-RADS 2 on T2W image, PI-RADS 5 on DWI, and PI-RADS 4 on DCE. Because the
lesion is in the transition zone, T2W is the dominant parameter, and the final PI-RADS score was PI-RADS 2. (a) Axial T2-weighted image.
(b) Axial ADC map. (c) Axial DWI with 𝑏 = 1400. (d) Axial DCE image. (e) Curve of the DCE image.
sessions. On these images a lesion is seen in the left transition
zone. On the T2-weighted images it is scored as PI-RADS 2
because it is a well-marginated area with homogenous low
signal intensity originating from a BPH nodule. On the DWI
it is scored as PI-RADS 5 because it is a focal area with low
signal intensity on the ADCmap and high signal intensity on
the calculated 𝑏1400 image. Furthermore, the lesion shows
a type 3 enhancement curve, with some focal, however not
asymmetric, enhancement.Therefore, it is scored as PI-RADS
4 on theDCE images. Because the individual PI-RADS scores
are not concordant, the dominant parameter determines
the final PI-RADS score. Since the lesion is located in the
transition zone, the dominant parameter is the T2WI and
therefore the final PI-RADS score for this lesion is PI-RADS
2. Nevertheless, this patient had a high clinical suspicion
for PCa because of his high PSA level and for that reason
MR-guided biopsy was performed of this PI-RADS 2 lesion.
Histopathological analysis of the biopsy cores confirmed that
there was no malignancy but BPH.
In conclusion, the PI-RADS classification is still work in
progress and will have further improvement in the future.
Furthermore, more studies have to be done to validate the
accuracy and interobserver variability.
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